Efficacy of EQNMT’s Psychedelic-Assisted Therapy Program

Take a Closer Look

Our therapeutic framework integrates neuroscience with various therapeutic tools from different traditions and can be applied with different psychedelic agents for a wide variety of conditions (trans-diagnostic).

Our efficacy data represents the results of 71 people (N=71) (unless otherwise specified) who participated in EQNMT’s psychedelic-assisted therapy program to date, resulting in a 98% success rate.

We commit to updating our data continually to provide a transparent picture of client outcomes.

Our success rate was determined by calculating the mean (average) scores of the following measures, from pre-retreat to 6 months post-retreat:

Beck Anxiety Scale (BAS)

The lower the score, the less anxious the person feels.

Beck Depression Inventory (BDI)

The lower the score, the less depressed the person feels.

Patient Health Questionnaire (PHQ9)

The data represents changes in self-reported depression. The lower the score, the less depressed the person feels.

Yale-Brown OCD Scale
(YBOCS)

The lower the score, the milder the OCD symptoms.

Hamilton Depression Scale
(HAM-D)

The lower the score, the less depressed the person feels.

World Health Organization Quality of Life Scale (WHOQoLS)

The WHOQoLS has four scales-

Phys = Physical
Psych = Psychological
Soc = Social
Env = Environmental

The higher the score, the better the quality of life.

The data portrayed below represents changes in self-reported substance use.

The graphs represent mean (average) scores of N (number)= 25 participants from pre-retreat to 6 months post-retreat.

N = 5 cocaine
N =12 cannabis
N = 18 alcohol

Scoring:

Below 50= Full remission
50-60= Partial remission
60-70= Mild-moderate substance use
Above 70= Clinically significant substance abuse

The initial data indicates promising, enduring outcomes for clients seeking relief from Depression, Anxiety, OCD and Substance Use by participating in EQNMT’s evidence-based psychedelic-assisted therapy programs.

The Science of Psychedelic-Assisted Therapy

Psilocybin therapy, which involves the controlled use of the psychoactive compound psilocybin found in certain mushrooms, has shown promise as an effective treatment for a range of mental health disorders. While research in this area is ongoing, several key neuroscientific mechanisms underlie its potential efficacy:

Disruption of Default Mode Network (DMN)

Psilocybin has been shown to temporarily disrupt the DMN, a network of brain regions associated with self-referential thoughts, rumination, and the sense of ego. Overactivity of the DMN is linked to conditions like depression, anxiety, and addiction. By reducing the DMN's activity, psilocybin may help individuals break free from entrenched thought patterns and gain new perspectives on their mental health issues.

Increased Brain Connectivity

Studies suggest that psilocybin can increase connectivity between different brain regions, facilitating novel connections and insights.

This can enhance cognitive flexibility and potentially help individuals reframe their experiences and emotions in a therapeutic context.

Emotional Processing

Psilocybin appears to promote the processing of unresolved emotions and traumatic memories.

This may enable individuals to confront and work through underlying issues, making it useful for conditions like depression, anxiety and post-traumatic stress disorder (PTSD).

Neuroplasticity

Psilocybin may promote neural plasticity, the brain's ability to rewire itself.

This can be crucial in breaking entrenched patterns of thought and behavior and fostering adaptive change in the brain.

Enhanced Mood and Perception

The compound can induce altered states of consciousness, characterized by shifts in perception and mood.

These experiences, under the guidance of trained therapists, can potentially provide individuals with a fresh perspective on their mental health issues and facilitate a more positive outlook.

Promoting Neurogenesis

Some studies suggest that psilocybin may promote neurogenesis, the growth of new brain cells.

This is an important factor in maintaining overall brain health and resilience, which can be relevant for mental health disorders.

Apply to Attend a Retreat

It's important to note that psilocybin therapy is still in its early stages of research, and its efficacy and safety need further investigation. Moreover, it should only be administered in a controlled, therapeutic setting under the guidance of trained professionals.

While it holds potential as a treatment option for certain mental health disorders, it is not a standalone solution and should be considered as part of a broader approach that may include psychotherapy and other interventions.

Multiple published studies showing the safety and efficacy of psychedelic-assisted therapy.

EQNMT combines the therapeutic approaches from all of these studies to overcome the limitation of each as a standalone treatment.

Click to View Studies